Sayna Norouzi, MD, is an assistant professor of medicine, clinical nephrologist, and founder and director of the glomerular disease and polycystic kidney disease clinics at Loma Linda University Medical Center.

Chee Kay Cheung MBChB PhD, is a consultant nephrologist and honorary senior lecturer at the University of Leicester.

Current Disease-Modifying Treatment Options in IgAN

In this segment, the panel discusses how the treatment landscape for IgA nephropathy is evolving with the introduction of disease-targeted therapies. They highlight targeted-release budesonide, formulated to act in the gut-associated lymphoid tissue, where galactose-deficient IgA1 is produced. This allows reduction of pathogenic IgA at its source while avoiding the broader immunosuppression seen with systemic steroids. The discussion also includes sparsentan, a dual endothelin receptor antagonist and angiotensin receptor blocker, which has shown meaningful reductions in proteinuria compared with standard RAAS blockade alone. These agents are contrasted with SGLT2 inhibitors, which remain part of optimized supportive care but do not directly address the underlying immune mechanism. The panel notes that while these therapies represent important progress, access and reimbursement may limit uptake in real-world settings. Still, they agree that these additions mark a shift toward disease-modifying treatment strategies rather than relying solely on supportive care.

Videos

In this segment, the panel discusses how the treatment landscape for IgA nephropathy is evolving with the introduction of disease-targeted therapies.

Video Series

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Optimizing the Timing of PCSK9 Therapy After an ASCVD Event

The panelists explore the question of when to initiate PCSK9 therapy following an ASCVD event. They note that evidence from large trials and real-world data supports the early introduction of PCSK9 inhibitors, often before hospital discharge, to maximize LDL-C lowering and reduce the risk of recurrent events. The experts point out that patients remain at the highest risk for a second event in the first year after an acute coronary syndrome, making this window crucial for aggressive lipid management. They also discuss how logistical barriers—such as prior authorizations and coordination between inpatient and outpatient teams—often delay therapy initiation. Early administration, the panelists emphasize, can improve adherence and long-term outcomes, particularly when combined with educational efforts and structured follow-up. Overall, the experts agree that integrating PCSK9 inhibitors into the acute-to-chronic care continuum represents a practical and evidence-based approach to optimizing secondary prevention in high-risk ASCVD patients.

Healthcare professionals discuss strategies for effectively lowering LDL cholesterol in patients post-cardiac events, emphasizing early intervention and tailored therapies.

Exploring the Therapeutic Potential of B-Cell Modulation in IgAN

The panel examines drug classes targeting the BAFF and APRIL pathways, which play key roles in the production and regulation of IgA-secreting plasma cells. The clinicians discuss how these therapies attempt to reduce the formation of harmful IgA complexes at the source, representing a more upstream approach compared to conventional supportive therapy. They also acknowledge questions surrounding long-term safety, dosing strategies, and patient selection for these newer interventions. Some participants express cautious optimism, noting that early trial data suggest meaningful reductions in proteinuria and stabilization of kidney function. However, they emphasize the importance of real-world experience and monitoring for immune-related side effects, as these therapies affect broader B-cell biology. The conversation highlights how targeted therapies may eventually be used in combination with supportive care to improve outcomes. Overall, the segment reflects a turning point toward therapeutic strategies focused on modifying disease rather than merely slowing progression.

The panel examines drug classes targeting the BAFF and APRIL pathways, which play key roles in the production and regulation of IgA-secreting plasma cells.

Princess Ogbogu, MD, from the University of Hospitals Rainbow Babies & Children’s Hospital

David Golden, MD, clinical associate professor of medicine at Johns Hopkins University School of Medicine.

a board-certified and fellowship-trained ear, nose, and throat (ENT) specialist at UT Health Houston

an internal medicine and pediatrics-trained allergist practicing in Mobile, Alabama.

HCPLive Five at ACAAI 2025

American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

 in Orlando, leading clinicians from UT Health Houston, the University of Alberta, Johns Hopkins University School of Medicine, and community allergy practices presented pivotal updates in asthma, immunology, dermatology, and anaphylaxis care. This HCPLive Five highlights emerging data across eosinophilic disorders, chronic rhinosinusitis, hereditary angioedema (HAE), anaphylaxis management, and atopic dermatitis, each offering clinicians new insights into rapidly evolving therapeutic landscapes.

Benralizumab Reduces HES Flare in Phase 3 Trial, With Princess Ogbogu, MD

Benralizumab significantly reduced flare events and fatigue in patients with hypereosinophilic syndrome (HES), according to phase 3 NATRON results presented at ACAAI 2025. In an interview with HCPLive, Princess Ogbogu, MD, of the University of Hospitals Rainbow Babies & Children’s Hospital, highlighted the therapy’s impact on time to first flare, annualized flare rates, and hematologic relapse, noting patients on benralizumab did significantly better than those on placebo. Improvements in PROMIS Fatigue scores emerged by week 4. Safety findings aligned with prior benralizumab data, with mostly mild adverse events.

Dupilumab Shows Promise for Allergic Fungal Rhinosinusitis in Phase 3 Trial, With Amber Luong, MD, PhD

Dupilumab demonstrated strong efficacy for allergic fungal rhinosinusitis (AFRS) in the phase 3 LIBERTY AIMS trial, offering a potential new option for this challenging CRSwNP subtype. Amber Luong, MD, PhD, from UT Health Houston, presented data at ACAAI 2025 showing significant improvements in sinus opacification, nasal polyp size, and congestion by weeks 24 and 52, with dupilumab reducing the need for oral steroids or surgery by 92%. The year-long study enrolled 62 rigorously diagnosed patients and met all primary and secondary endpoints. Safety findings aligned with dupilumab’s known profile.

Sebetralstat Shows Promise for On-Demand HAE Treatment in Children, With Adil Adatia, MD

Adil Adatia, MD, from the University of Alberta, presented interim KONFIDENT-KID findings showing that oral sebetralstat safely and rapidly reduced symptoms of hereditary angioedema (HAE) attacks in children aged 2 - 11 years. The oral plasma kallikrein inhibitor, already approved for patients ≥12, was administered within 30 minutes of symptom onset, with a median time to first improvement of four hours. No treatment-emergent adverse events were reported, and pharmacokinetic data aligned with adult studies. Adatia emphasized the promise of a fast-dissolving oral option for young children, noting its potential to replace challenging IV therapies and transform timely, at-home pediatric HAE management.

Sublingual Epinephrine Film Rapidly Works in Children, With David Golden, MD

David Golden, MD, from Johns Hopkins, presented phase 1 data showing that AQST-109 (Anaphylm), a sublingual epinephrine film, rapidly reaches therapeutic levels in children, triggering cardiovascular effects within 2 minutes. In 32 participants aged 7 – 17 years, pharmacokinetics and pharmacodynamics closely mirrored adult findings, with therapeutic plasma levels achieved by 5 - 8 minutes and peak concentrations at 10 minutes. Heart rate and blood pressure rose early, confirming fast onset. Golden emphasized that the needle-free film performed comparably to adult data and may offer an effective alternative to intranasal and injectable epinephrine options for children at risk of severe allergic reactions.

Tapinarof Shows Early, Sustained Benefits in Pediatric Atopic Dermatitis, With Druhan Howell, MD

Druhan Howell, MD, a pediatrics-trained allergist practicing in Mobile, Alabama, highlighted sub-analysis data from the ADORING 1 and 2 trials showing that 1% tapinarof cream delivers early, sustained benefits in children aged 2–17 with atopic dermatitis (AD). Across 654 pediatric patients, including those with asthma, allergic rhinitis, or food allergies, tapinarof improved skin clearance, eczema severity, itch, sleep, and overall symptom burden as early as week 1, with effects maintained through week 8. EASI-75 and vIGA-AD™ response rates were significantly higher than vehicle, regardless of comorbidities. Safety was consistent with prior findings, with no new signals.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Identifying Candidates for PCSK9 Therapy After ASCVD Events

The panelists discuss how to identify appropriate candidates for PCSK9 inhibitor therapy following an ASCVD event. They emphasize that treatment decisions should be guided by both LDL-C levels and overall risk profile, with particular attention to patients who remain above guideline-recommended thresholds despite maximally tolerated statin and ezetimibe therapy. The experts highlight that individuals with recurrent cardiovascular events, multivessel disease, or premature ASCVD are at especially high risk and stand to benefit from early PCSK9 inhibitor initiation. The conversation also touches on secondary prevention timing, noting that introducing PCSK9 inhibition soon after an acute event may help achieve rapid and durable LDL-C reduction, potentially lowering near-term event risk. The panelists agree that improved access, clinician education, and integration of lipid management into the hospital-to-outpatient transition are key to expanding appropriate PCSK9 use and reducing the persistent burden of recurrent ASCVD events in high-risk patients.

Healthcare professionals explore effective strategies for LDL cholesterol management, emphasizing patient involvement and innovative therapies for optimal outcomes.

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

Articles

This systematic review and meta-analysis looked at research on the efficacy and safety of topical roflumilast 0.3% in patients with plaque psoriasis.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Topical Roflumilast 0.3% Effective, Safe in Systematic Review of Psoriasis Data

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Oral bradykinin B2 receptor antagonist resolved HAE attacks in under 90 minutes, with most patients needing only a single dose and no rescue medication.


Pharvaris’ Deucrictibant Provides Rapid Relief for HAE in Phase 3 RAPIDe-3 Trial

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

A longitudinal cohort study shows a lack of correlation between decreased proteinuria levels and improved treatment, renal responses in patients. 


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Low-Grade Proteinuria Not Tied to Improved Renal Outcomes in Lupus Nephritis

Silas is the senior vice president, content, at MJH Life Sciences. He began his career at MJH in 2011 as a Web Editor on OncLive. From this role, he moved into managing the social media across the organization and then into broader roles across the content department, first taking on management of HCPLive.

Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology and NeurologyLive, and for quickly transforming acquisitions into high-functioning business units. Follow him on X @

Rusfertide shows promising results as a first-in-class therapy for polycythemia vera, demonstrating sustained hematocrit control and safety in recent studies.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Hematology

Rusfertide Maintains Hematocrit Control Through 52 Weeks in VERIFY

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Catch up with major trial results, key clinician insights, and more.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Type 1 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

5 Endocrinology Headlines You Missed in November 2025

Naeem Bhojani, MD, associate professor and clinical researcher at the University of Montreal.

Explore the latest advancements in kidney stone treatment, focusing on suction technology and its impact on surgical outcomes and patient safety.

This Year In Medicine

Modernizing Kidney Stone Treatment: Devices, Data, and Clinical Impact

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

This FDA News Month in Review provides a round-up of regulatory decisions from November 2025.

FDA News

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Dyslipidemia

5 FDA Headlines You Missed in November 2025

Chari Cohen, DrPH, MPH, is the President of the Hepatitis B Foundation.

Cohen cites past failures with risk-based hepatitis B vaccination and voices concerns about the CDC APIC vote for individual-based decision-making.

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Clinical Concerns Over the ACIP Infant Hepatitis B Vaccine Decision, With Chari Cohen, DrPH, MPH

a psychiatrist and Chief Medical Officer at HMNC Brain Health

As the FDA strengthens AI standards after its recent meeting, a new AI-assisted genetic tool shows promise for pinpointing patients who may respond to a vasopressin blocker.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

New Genetic Tool Shows Promise for Targeted MDD Treatment, With Hans Eriksson, PhD, MD

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The 8-3 APIC vote recommends individual-based decision-making for HBV vaccination in infants born to women who test negative for the virus.

Latest News

Current Disease-Modifying Treatment Options in IgAN

Optimizing the Timing of PCSK9 Therapy After an ASCVD Event

Exploring the Therapeutic Potential of B-Cell Modulation in IgAN

HCPLive Five at ACAAI 2025

Identifying Candidates for PCSK9 Therapy After ASCVD Events